Our team's objectives are to: (i) develop new analytic strategies to study the genomic/genetic determinants of susceptibility to and evolutions of human diseases; (ii) implement these strategies using free software packages (R LBE, GPLTR, ASPBay, ElstonStewart, and Gaston); (iii) transfer these results for use in public health; and (iv) develop the teaching of genomics and statistical genetics.
The team participates in the ABIRISK consortium, an interdisciplinary and multicenter project supported by the Innovative Medicine Initiative (IMI), a European project with partners including the AP-HP, INSERM, and the University of Paris-South. The objective is to identify predictive/prognostic factors for the appearance of antidrug antibodies (or ADAs) for several biological therapies (monoclonal antibodies, Factor VIII, and others) and diseases (multiple sclerosis, rheumatoid arthritis, chronic inflammatory bowel diseases, and hemophilia A). We coordinate Workpackage 4 (Construction of a database, retrospective and prospective studies, analysis, predictive modeling).
The team also participates in the PestiBG project (2014 Cancer Plan), which studies the pesticides exposure of a cohort of farmers (biomarkers and analysis of genetic polymorphisms), coordinated by Élisa Boutet (TOXALIM, INRA, University Paul-Sabatier, Toulouse). Several other collaborations are underway, especially with INSERM partners. We are also a member of two AP-HP University-Hospital departments (DHU): HEPATINOV and TORINO.